TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 24nMAssay Description:Binding affinity to PPARgamma (unknown origin) by lanthascreen TR-FRET assayMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 90nMAssay Description:Binding affinity to PPARgamma (unknown origin) by lanthascreen TR-FRET assayMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 154nMAssay Description:Binding affinity to PPARgamma (unknown origin) by lanthascreen TR-FRET assayMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 160nMAssay Description:Inhibition of PPARgamma (unknown origin) phosphorylation at pS273 residueMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 580nMAssay Description:Inhibition of PPARgamma (unknown origin) phosphorylation at pS273 residueMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 4.40E+3nMAssay Description:Inhibition of PPARgamma (unknown origin) phosphorylation at pS273 residueMore data for this Ligand-Target Pair
Affinity DataIC50: 4.60E+3nMAssay Description:Inhibition of recombinant human CYP2C9 preincubated for 10 mins followed by NADPH addition and measured at 20 to 50 mins by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: 9.75E+4nMpH: 7.5 T: 2°CAssay Description:The DNA-binding competition assay was performed in 25 μL, in black 384-well plates, using either 30 mM HEPES (N-2-Hydroxyethylpiperazine-N'-2-Etha...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20E+5nMpH: 7.5 T: 2°CAssay Description:The DNA-binding competition assay was performed in 25 μL, in black 384-well plates, using either 30 mM HEPES (N-2-Hydroxyethylpiperazine-N'-2-Etha...More data for this Ligand-Target Pair
Affinity DataIC50: 1.63E+5nMpH: 7.5 T: 2°CAssay Description:The DNA-binding competition assay was performed in 25 μL, in black 384-well plates, using either 30 mM HEPES (N-2-Hydroxyethylpiperazine-N'-2-Etha...More data for this Ligand-Target Pair
Affinity DataIC50: 2.20E+5nMpH: 7.5 T: 2°CAssay Description:The DNA-binding competition assay was performed in 25 μL, in black 384-well plates, using either 30 mM HEPES (N-2-Hydroxyethylpiperazine-N'-2-Etha...More data for this Ligand-Target Pair
Affinity DataIC50: 3.27E+5nMpH: 7.5 T: 2°CAssay Description:The DNA-binding competition assay was performed in 25 μL, in black 384-well plates, using either 30 mM HEPES (N-2-Hydroxyethylpiperazine-N'-2-Etha...More data for this Ligand-Target Pair
Affinity DataIC50: 3.41E+5nMpH: 7.5 T: 2°CAssay Description:The DNA-binding competition assay was performed in 25 μL, in black 384-well plates, using either 30 mM HEPES (N-2-Hydroxyethylpiperazine-N'-2-Etha...More data for this Ligand-Target Pair
Affinity DataIC50: 3.48E+5nMpH: 7.5 T: 2°CAssay Description:The DNA-binding competition assay was performed in 25 μL, in black 384-well plates, using either 30 mM HEPES (N-2-Hydroxyethylpiperazine-N'-2-Etha...More data for this Ligand-Target Pair
Affinity DataIC50: 3.75E+5nMpH: 7.5 T: 2°CAssay Description:The DNA-binding competition assay was performed in 25 μL, in black 384-well plates, using either 30 mM HEPES (N-2-Hydroxyethylpiperazine-N'-2-Etha...More data for this Ligand-Target Pair
Affinity DataIC50: 4.81E+5nMpH: 7.5 T: 2°CAssay Description:The DNA-binding competition assay was performed in 25 μL, in black 384-well plates, using either 30 mM HEPES (N-2-Hydroxyethylpiperazine-N'-2-Etha...More data for this Ligand-Target Pair
Affinity DataIC50: 1.11E+6nMpH: 7.5 T: 2°CAssay Description:The DNA-binding competition assay was performed in 25 μL, in black 384-well plates, using either 30 mM HEPES (N-2-Hydroxyethylpiperazine-N'-2-Etha...More data for this Ligand-Target Pair
Affinity DataIC50: 2.88E+6nMpH: 7.5 T: 2°CAssay Description:The DNA-binding competition assay was performed in 25 μL, in black 384-well plates, using either 30 mM HEPES (N-2-Hydroxyethylpiperazine-N'-2-Etha...More data for this Ligand-Target Pair
Affinity DataIC50: 3.80E+6nMpH: 7.5 T: 2°CAssay Description:The DNA-binding competition assay was performed in 25 μL, in black 384-well plates, using either 30 mM HEPES (N-2-Hydroxyethylpiperazine-N'-2-Etha...More data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataEC50: 27nMAssay Description:Agonist activity at Gal4-fused PPARgamma (unknown origin) expressed in human U2OS cells co-transfected with pSG5 expression vector preincubated for 4...More data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataEC50: >5.00E+4nMAssay Description:Agonist activity at Gal4-fused PPARgamma (unknown origin) expressed in human U2OS cells co-transfected with pSG5 expression vector preincubated for 4...More data for this Ligand-Target Pair